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Introduction
Migraine is a common disorder that can be episodic or
chronic. It is estimated that approximately 14.4% of
women and 4.5% of men experience migraine in the
Taiwanese population.1 Approximately 1.8% of the pop-
ulation also suffers from transformed migraine (TM).2
Patients with TM have a pattern of moderate, non-
descript background headache pain with superim-
posed episodes of migraine in which the frequency 
of attacks increases until a pattern of daily headache
evolves. The diagnosis of TM is based on having
more than 15 days of headache per month lasting
more than 4 hours per day with a duration of more
than 3 months (Silberstein-Lipton criteria).3 Analgesic
overuse is associated with an evolution toward TM,
although the exact causal relationship is not clear.4
Recurrent disabling migraine induces significant func-
tional limitations and imposes large individual, social,
and economic burdens. Thus, the goals of long-term
headache treatment are to reduce the frequency, sever-
ity, and disability associated with migraine attacks.
Therefore, preventive or prophylactic treatment is
indicated for TM patients.
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Chronic pain relief has been achieved with intra-
muscular injections of BOTOX® (botulinum toxin
type A [BoNT-A]; Allergan Inc., Irvine, CA, USA)
for the treatment of primary and secondary cervical
dystonia as well as spasticity.5–7 In reviewing the
patient selection criteria, inclusion and exclusion cri-
teria, the number of baseline migraine headaches 
per month and the outcome measures used, there is 
a wide range of patients treated.8–10 Furthermore,
there have been differences in the dosage of BoNT-A
used, the location of the injection sites in the face,
scalp and neck regions, and whether the assessment of
the primary outcome variable was determined after 
1 or more treatment sessions. Two widely advocated
injection site methods have been utilized. Blumenfeld8
identified BoNT-A injection sites based on the find-
ing of local tenderness on muscle palpation. This 
is a common practice in the evaluation of patients
with cervical dystonia who are to receive BoNT-A.6
Muscle tenderness could represent localized muscle
contraction or a symptom of muscle allodynia.11
In this study, we analyzed the use of BoNT-A to
treat TM either by injections into the scalp and facial
regions only or combined with injections to sites
(determined by muscle tenderness) in the neck and
shoulder muscles. The aims of this study were to estab-
lish dosing, and the choice and number of injection
sites required to provide optimal results for Taiwanese
patients with TM.
Methods
Patients
This study included patients who were treated with
BoNT-A from July 2003 to May 2004. Subjects consid-
ered for participation were the first author’s patients
who: (1) met the criteria for TM (Silberstein-Lipton cri-
teria);3 (2) were refractory to oral medication or intole-
rant of the adverse effects of preventive drugs; and (3)
were without secondary causes for headache. We re-
viewed the records of 32 patients with TM from patients
seen in our regional teaching hospital-based Headache
Clinic. Two patients were lost to follow-up and were
not included in any data analysis. Thirty consecutive pa-
tients, aged 25–75 years, with complete records and
who satisfied the inclusion criteria were recruited. Pa-
tients were injected with BoNT-A for only 1 session and
followed-up for 3 months. Exclusion criteria were
planned or actual pregnancy, lactation, known allergy or
sensitivity to the study medication or its components,
and prior injection of anesthetic or steroid into the mus-
cles to be injected in the month prior to study entry.
Injection method
The total dose of BoNT-A to be administered was
determined by the number of injection sites. After
placing the patient in a sitting position, patients were
questioned on the anatomic location of the headache.
The frontalis, temporalis, and posterolateral neck and
shoulder regions were palpated by the first author to
identify areas of muscle tenderness, which were iden-
tified as tender points (TPs) in this study. Intramuscular
injections using sterile technique were administered
using 1-mL tuberculin syringes with 30-gauge needles.
BoNT-A 100U vial was reconstituted with preservative-
free 0.9% saline to yield 2.5 U/0.1 mL. All patients
received injections into the procerus (5 U, 1 site),
corrugator (2.5 U each, 2 sides), frontalis (2.5 U
each, 2 sites on each side), and anterior and pre-
auricular temporalis (2.5 U each, 2 sites on each side)
for a total dose of 30 U. If there were TPs on the 
palpated muscles, some of these patients were ran-
domized to receive injections into the tender muscles.
We designed the method for the injection sites of 
tender muscles and dose of BoNT-A according to
Blumenfeld et al12: occipitalis (5U), trapezius (5–10 U,
divided into 2–3 sites), sternocleidomastoid (5–10 U,
divided into 2–3 sites), scalene (5–10 U), levator
scapulae (5–10 U), semispinalis (5 U, divided into 
2 sites) or splenius capitis (5–10 U, divided into 1–3
sites) muscles.
Outcome measures
The outcome measures were reduction in headache
frequency and intensity, and the data were collected
and recorded at baseline and at each clinic visit. At
baseline, patients reported headache frequency and
intensity in headache diaries, starting 1 month before
BoNT-A injection; thus, the baseline data were also
the pre-injection data. The patients’ headache diaries
were post-injection data after BoNT-A treatment. 
In order to be included in the study analysis, chart
notes had to document headache frequency data and
headache intensity data for both the baseline and post-
injection visits. Headache intensity was recorded using
a 4-point scale (0 = none, 1 = mild, 2 = moderate,
3 = severe). At post-injection visits, patients were asked
to assess their symptoms compared with those at base-
line, and treatment was reported as being effective if
there was at least a 50% reduction in the number of
headache days or in headache intensity. Only data
from patients’ baseline visit and post-injection visit
were analyzed based on the headache diaries. All data
included in this study were collected during a 3-month
period. Data from visits after 3 months and missing
data were excluded from the analysis.
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Statistical analysis
Analyses of efficacy parameters were performed using
paired-sampled statistics, analysis of variance, and χ2
tests. Baseline and post-injection scores for headache
days, headache intensity and patients’ subjective reports
were evaluated for month 1, 2 and 3 post-injection.
The efficacy parameter was reduction of headache
days per month and headache intensity in month 
3 compared with the baseline month. The signifi-
cance level was set at p < 0.05.
Results
Thirty patients with TM were recruited in this study,
which was 3% of the total number of headache patients
under the care of our Headache Clinic during this time
period. The mean age of the 30 patients in this study
was 51.7±13.2 years (range, 25–75 years); 20 patients
(67%) were women. Eighty percent of patients had
medication overuse (24 of 30). Overall, the mean
BoNT-A dose was 33U (range, 30–65U). Mean body
mass index was 25.5kg/m2 (range, 17.9–44.1 kg/m2).
Twenty-four of 30 patients received fixed-site treat-
ment of 30 U, and 6 patients received combination
treatment (> 30 U; mean total dose, 45 U), i.e. addi-
tional injection sites in the splenius capitis and/or
occipitalis and/or trapezius muscles.
Overall, 27 of the 30 patients (90%) surveyed
reported effective treatment with BoNT-A (at least a
50% reduction in the number of headache days or
headache intensity). Eleven patients (37%) were free of
headache. A significant reduction in headache fre-
quency was observed (paired t test, p < 0.001) with a
decrease in the number of headache days per month
from 27.2 at baseline to 8.1 (70% reduction) in month 3
(Table 1). Headache intensity decreased significantly
from 2.3 ± 0.6 points at baseline to 0.8 ± 0.7 points
(65% reduction; paired t test, p < 0.001) (Table 1).
TPs in the splenius capitis and/or occipitalis
and/or trapezius muscles were identified in 14 of the
30 patients. We found no significant difference in
headache days per month or headache intensity
between those with and without TPs at baseline
(Table 1). TM patients with TPs were randomized
into 2 groups: Group I received 30 U by the fixed-site
approach; Group II received additional injections in a
combination paradigm (mean total dose, 45 U; dose
range, 40–55 U). The number of headache days per
month decreased from 27 at baseline to 11.3 days
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Table 1. Patient characteristics
All patients (n = 30) TM without TPs (n = 16) TM with TPs (n = 14)
Mean age (yr) 52 54 50
Gender
Female 20 10 10
Male 10 6 4
HA intensity, baseline
Mild 2 0 2
Mild to moderate 4 1 3
Moderate 8 6 2
Moderate to severe 5 4 1
Severe 11 5 6
Mean 2.3 2.3 2.2
HA intensity, post-injection 0.8 0.8 0.8
HA days per month, baseline 27.2 27.3 27.2
HA days per month, post-injection 8.1 6.9 9.5
Aura 5 4 1
Associated symptoms
Nausea or vomiting 15 7 8
Photophobia and phonophobia 15 10 5
Medication overuse 24 13 11
Analgesic 15 7 8
Combined medication 9 6 3
HA = headache; TM = transformed migraine; TPs = tender points.
(58% reduction) in Group I (8 of 14 patients), while
the number of headache days per month decreased
from 27.5 at baseline to 7.2 days (74% reduction) in
Group II (6 of 14 patients) (Figure 1). Headache
intensity decreased from 1.9 at baseline to 0.9 
(53% reduction) in Group I, while headache intensity
decreased from 2.8 at baseline to 0.7 (75% reduction)
in Group II (Figure 2).
No systemic reactions or treatment-related adverse
events, including blepharoptosis, diplopia, and mus-
cle weakness at the injection sites, were noted in this
study.
Discussion
In this study, BoNT-A was shown to be a safe and
well-tolerated treatment for TM patients, significantly
reducing headache frequency and intensity.
A prospective, double-blind, vehicle-controlled
study of 25 U and 75 U BoNT-A treatment in 123
patients with approximately 4 moderate-to-severe
migraine attacks per month demonstrated that 25 U
of BoNT-A, but not 75 U, resulted in a significant
reduction in moderate-to-severe migraine frequency
at months 2 and 3 as well as reduction in mean sever-
ity at months 1, 2 and 3 (p < 0.05).11 In Behmand 
et al’s study, 24 of 29 patients (83%) with migraine
reported a positive response to the injection of a total
dose of 50 U BoNT-A.13 These results prompted 
us to study the effect of a lower dose of BoNT-A
compared to many of the published studies.14
In our study, there was no significant difference 
in headache days per month or headache intensity
between TM patients with TPs and those without 
TPs at baseline. For comparison of the efficacy of the
2 different injection paradigms, TM patients with TPs
were randomized into 2 groups: Group I received
30 U by the fixed-site approach and Group II received 
additional injections in a combination paradigm.
Tenderness was only identified in the splenius capitis
and/or occipitalis and/or trapezius muscles. The
patients who received the combination paradigm
seemed to experience a greater reduction in the num-
ber of headache days per month and headache inten-
sity compared to those who were treated with the
fixed-site approach. However, small case numbers in
each group prevented further statistical analysis.
Interestingly, there was no significant difference in
the reduction of headache days per month and
headache intensity between the TM patients who
received the combination paradigm and those with-
out TPs, which implies that a larger dose of BoNT-A
may be needed in TM patients with TPs to achieve a
similar efficacy as in those without TPs.
Blumenfeld et al12 identified BoNT-A injection
sites based on the finding of local tenderness on muscle
palpation. This is a common practice in the evaluation
and treatment of patients with cervical dystonia who
receive BoNT-A. Muscle tenderness can represent the
pain of focal muscle contraction or a symptom of allo-
dynia.15 These TPs from pericranial muscles might act as
permanent and powerful triggers of migraine attacks.16
It is understandable that eliminating them directly
might avoid migraine attacks.
Dodick et al observed that in some patients, mus-
cle function returned after 3 months, but the effects
of the drug on the elimination of the headaches per-
sisted for longer.14 We made the same observation in
our study, but the duration of the effect of BoNT-A
could not be calculated exactly due to variable follow-
up duration. The duration of effect of BoNT-A for
migraine was not studied in the current report. Our
study focused on 1-session injection for our TM
patients because in some patients, a single treatment
might be enough to break the cycle of chronic
J Chin Med Assoc • December 2007 • Vol 70 • No 12538
Y.C. Liu, et al
30
25
20
15
10
5
0
Baseline Post-injection
30 U
TM without
TPs (n = 16)
TM with 
TPs (n = 8)
TM with
TPs (n = 6)
Group I (30 U) Group II (> 30 U)
Figure 1. Reduction in the number of headache days per month
with BoNT-A treatment. A greater reduction in headache days per
month was found in Group I than in Group II. TPs = tender points.
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Figure 2. Reduction in headache intensity with BoNT-A treatment.
A greater reduction in headache intensity was found in Group I
than in Group II. TPs = tender points.
headaches and there would be no need for repeated
injections.17 The cost of BoNT-A was another major
issue because patients had to pay for it themselves.
A randomized, placebo-controlled, parallel design
study of 200 U BoNT-A treatment in 60 patients
with chronic daily headache (CDH) found that the
BoNT-A group strongly tended to improve over the
entire 12-week period, 33 ± 23 days vs. 24 ± 16 days
without headache (p = 0.07), but did not meet the 
a priori significance criteria.18 The subject global impres-
sions (p<0.05), subject change in headache impression
(p < 0.005), and investigator global impressions 
(p < 0.001) all improved in the BoNT-A group com-
pared with placebo. But the authors employed only 
1 strategy—“follow the pain”—for all patients with
CDH, including chronic tension-type headache
(CTTH) and chronic migraine (CM), resulting in
unsatisfactory benefits and the tendency to improve
more in patients with CTTH than those with CM.
The authors also noted the potential weaknesses of
their study that included non-optimized injection
technique and dose. The injection strategy and dose
of BoNT-A may be crucial in the efficacy of BoNT-A
in the treatment of CDH.
Even though the precise mechanism by which
headache is reduced is not known, based on limited
in vitro and in vivo data, it is possible that BoNT-A
treatment may reduce the local release of nociceptive
neuropeptides,19,20 and have either direct or indirect
effects on central sensitization.21,22 In all patients
treated in this study, the injection sites included facial
and scalp regions in the distribution of the trigeminal
nerve, which is believed to be important in the patho-
genesis of migraine.23 The rationale for the use of
intradermal and intramuscular BoNT-A injections in
these regions relates to a proposed mechanism of
action of BoNT-A: that there may be a neuromodula-
tory effect of afferent inputs to the trigeminal nucleus
from the scalp, skin and muscle within the first branch
of the trigeminal nerve and cervical dermatomal dis-
tribution. It is hypothesized that BoNT-A has its
effect not by direct muscle relaxation but by effects
on afferent inputs into the trigeminal nucleus.20
Our results suggest that BoNT-A might be an
effective prophylactic treatment for TM. In treating
Taiwanese and possibly other Asian TM patients, we
suggest a starting dose of at least 30 U of BOTOX®.
If there is significant muscle tenderness in the poste-
rior scalp, neck and shoulder musculature, then con-
sideration can be given to additional sites.
The weaknesses of this study include: (1) no placebo
control group; (2) a retrospective design; and (3) small
case number. These may limit the interpretation of
the results. With respect to dosing of the neck exten-
sor and rotator muscles, caution is advised. Dosing to
these muscles should be reduced from the standard
doses used in treating cervical dystonia given the risk of
inducing weakness, particularly in the extensor neck
muscles (splenius capitis and semispinalis). Interestingly,
Relja and Telarovic24 have shown that in cervical dys-
tonia, benefit for pain can be achieved at a dose lower
than that required to alter posture. Few studies pub-
lished have examined the role of BoNT-A in TM,25 and
dosing requirements for non-Caucasian patients with
migraine should be explored.26 Further study of dos-
ing and injection technique in the Asian TM patient
population appears warranted given our initial results,
the theoretical rationale for the use of BoNT-A, and the
significant headache-associated disability experienced
by these patients.
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